Arecor is a globally focused biopharmaceutical company that is targeting improving patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying the Group’s innovative proprietary formulation technology platform, Arestat™, the Group is developing an internal portfolio of proprietary products, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their partners’ therapeutic products, supported by an extensive patent portfolio.
The Group’s current focus of internal proprietary product development can be divided into two product classes: diabetes and specialty hospital care. In addition, the Group also develops novel enhanced formulations of its partners’ biological products that include biosimilars, biological products and vaccines, which are derived from the Group’s formulation development and technology licensing programmes and are referred to as “Technology Partnerships”.
Inaugural Annual Report
Having helped Arecor and their advisers with the production of their IPO admission document when they floated on AIM on 3rd June 2021, the Perivan shareholder communications team were delighted to provide their annual report design and production expertise for their inaugural report as a listed company which was published to 27th April, at this important stage of their corporate journey.
Perivan specialise in the production and publication of financial documents relating to shareholder and investor communications for quoted companies, private companies and open and closed-ended funds.